(MESO) Mesoblast - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.884m USD | Total Return: 40.4% in 12m

Cell Therapies, Regenerative Medicine, Stem Cells
Total Rating 11
Safety 34
Buy Signal -0.57
Biotechnology
Industry Rotation: -8.2
Market Cap: 1.88B
Avg Turnover: 2.25M
Risk 3d forecast
Volatility75.4%
VaR 5th Pctl11.4%
VaR vs Median-9.37%
Reward TTM
Sharpe Ratio0.69
Rel. Str. IBD39.2
Rel. Str. Peer Group26.8
Character TTM
Beta1.625
Beta Downside1.203
Hurst Exponent0.347
Drawdowns 3y
Max DD82.19%
CAGR/Max DD0.36
CAGR/Mean DD0.84
EPS (Earnings per Share) EPS (Earnings per Share) of MESO over the last years for every Quarter: "2021-03": -0.22, "2021-06": -0.17, "2021-09": -0.17, "2021-12": -0.2, "2022-03": -0.16, "2022-06": -0.17, "2022-09": -0.12, "2022-12": -0.1574, "2023-03": -0.13, "2023-06": -0.14, "2023-09": -0.1317, "2023-12": 0, "2024-03": 0, "2024-06": null, "2024-09": -0.28, "2024-12": -0.04, "2025-03": 0, "2025-06": -0.04, "2025-09": -0.07,
Last SUE: 0.17
Qual. Beats: 0
Revenue Revenue of MESO over the last years for every Quarter: 2021-03: 1.913, 2021-06: 1.996, 2021-09: 3.594, 2021-12: 2.382, 2022-03: 2.011, 2022-06: 2.224, 2022-09: 1.443, 2022-12: 1.98, 2023-03: 1.939, 2023-06: 2.139, 2023-09: 1.694, 2023-12: 1.694, 2024-03: 1.257, 2024-06: 1.257, 2024-09: 1.578, 2024-12: 1.578, 2025-03: 7.021, 2025-06: 7.021, 2025-09: null,
Rev. CAGR: 11.36%
Rev. Trend: 31.2%
Last SUE: -4.00
Qual. Beats: -1

Warnings

Share dilution 1029.5% YoY

Interest Coverage Ratio -5.8 is critical

Beneish M-Score 1.00 > -1.5 - likely earnings manipulation

Altman Z'' -1.43 < 1.0 - financial distress zone

Volatile

Tailwinds

Confidence

Description: MESO Mesoblast

Mesoblast Limited (MESO) is an Australian biotechnology firm specializing in the development of regenerative medicine therapies. The company utilizes a proprietary platform based on mesenchymal lineage cells to target systemic inflammatory conditions, cardiovascular diseases, and chronic pain. Its lead product candidate, Remestemcel-L, is currently undergoing Phase III clinical trials for multiple indications, including acute graft versus host disease and chronic heart failure.

The biotechnology sector typically operates on a high-risk, research-intensive business model where companies rely on strategic partnerships and intellectual property to fund long-term clinical development. Mesoblast maintains collaborations with global entities such as Tasly Pharmaceutical Group and Grünenthal to facilitate the commercialization and distribution of its cellular therapies across international markets.

Regenerative medicine focuses on repairing or replacing damaged human cells and tissues, a field that requires significant regulatory navigation before product approval. For a deeper look into these regulatory milestones and financial metrics, ValueRay provides additional analytical tools. The company’s pipeline also includes treatments for rheumatoid arthritis and diabetic nephropathy, reflecting a diversified approach to cellular medicine.

Headlines to Watch Out For
  • FDA approval decision for Remestemcel-L in pediatric graft versus host disease
  • Clinical trial results for chronic low back pain and heart failure therapies
  • Commercial partnership milestones and royalty payments from global strategic collaborators
  • Cash runway duration and potential capital raises for late-stage product development
  • Regulatory pathway clarity for mesenchymal lineage cell platform across multiple indications
Piotroski VR-10 (Strict) 0.5
Net Income: -102.1m TTM > 0 and > 6% of Revenue
FCF/TA: -0.06 > 0.02 and ΔFCF/TA -1.28 > 1.0
NWC/Revenue: 432.7% < 20% (prev -52.03%; Δ 484.7% < -1%)
CFO/TA -0.07 > 3% & CFO -51.2m > Net Income -102.1m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 1.58 > 1.5 & < 3
Outstanding Shares: last quarter (1.29b) vs 12m ago 1.03k% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 2.40% > 50% (prev 0.90%; Δ 1.49% > 0%)
Interest Coverage Ratio: -5.84 > 6 (EBITDA TTM -58.2m / Interest Expense TTM 10.7m)
Altman Z'' -1.43
A: 0.10 (Total Current Assets 202.5m - Total Current Liabilities 128.1m) / Total Assets 782.3m
B: -1.34 (Retained Earnings -1.05b / Total Assets 782.3m)
C: -0.09 (EBIT TTM -62.4m / Avg Total Assets 717.8m)
D: 2.77 (Book Value of Equity 574.7m / Total Liabilities 207.6m)
Altman-Z'' = -1.43 = CCC
Beneish M 1.00
DSRI: 8.80 (Receivables 43.3m/1.69m, Revenue 17.2m/5.90m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.83 (AQ_t 0.73 / AQ_t-1 0.88)
SGI: 2.91 (Revenue 17.2m / 5.90m)
TATA: -0.07 (NI -102.1m - CFO -51.2m) / TA 782.3m)
Beneish M = 4.60 (Cap -4..+1) = D
What is the price of MESO shares?

As of May 24, 2026, the stock is trading at USD 14.98 with a total of 144,346 shares traded.
Over the past week, the price has changed by +1.40%, over one month by -3.43%, over three months by -8.87% and over the past year by +40.35%.

Is MESO a buy, sell or hold?

Mesoblast has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy MESO.

  • StrongBuy: 1
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the MESO price?
Analysts Target Price 35 133.6%
Mesoblast (MESO) - Fundamental Data Overview as of 20 May 2026
P/E Forward = 454.5455
P/S = 28.8189
P/B = 3.316
Revenue TTM = 17.2m USD
EBIT TTM = -62.4m USD
EBITDA TTM = -58.2m USD
Long Term Debt = 60.1m USD (from longTermDebt, last quarter)
Short Term Debt = 69.1m USD (from shortTermDebt, last quarter)
Debt = 143.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.27m
Net Debt = 13.8m USD (calculated: Debt 143.4m - CCE 129.6m)
Enterprise Value = 1.90b USD (1.88b + Debt 143.4m - CCE 129.6m)
Interest Coverage Ratio = -5.84 (Ebit TTM -62.4m / Interest Expense TTM 10.7m)
EV/FCF = -37.70x (Enterprise Value 1.90b / FCF TTM -50.3m)
FCF Yield = -2.65% (FCF TTM -50.3m / Enterprise Value 1.90b)
 FCF Margin = -292.7% (FCF TTM -50.3m / Revenue TTM 17.2m)
 Net Margin = -593.9% (Net Income TTM -102.1m / Revenue TTM 17.2m)
 Gross Margin = unknown ((Revenue TTM 17.2m - Cost of Revenue TTM 53.1m) / Revenue TTM)
 Tobins Q-Ratio = 2.43 (Enterprise Value 1.90b / Total Assets 782.3m)
Interest Expense / Debt = 7.45% (Interest Expense 10.7m / Debt 143.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -49.3m (EBIT -62.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.58 (Total Current Assets 202.5m / Total Current Liabilities 128.1m)
Debt / Equity = 0.25 (Debt 143.4m / totalStockholderEquity, last quarter 574.7m)
 Debt / EBITDA = -0.24 (negative EBITDA) (Net Debt 13.8m / EBITDA -58.2m)
 Debt / FCF = -0.27 (negative FCF - burning cash) (Net Debt 13.8m / FCF TTM -50.3m)
 Total Stockholder Equity = 557.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.23% (Net Income -102.1m / Total Assets 782.3m)
RoE = -6.35% (Net Income TTM -102.1m / Total Stockholder Equity 1.61b)
RoCE = -3.74% (EBIT -62.4m / Capital Employed (Equity 1.61b + L.T.Debt 60.1m))
 RoIC = -7.04% (negative operating profit) (NOPAT -49.3m / Invested Capital 700.9m)
 WACC = 11.29% (E(1.88b)/V(2.03b) * Re(11.70%) + D(143.4m)/V(2.03b) * Rd(7.45%) * (1-Tc(0.21)))
Discount Rate = 11.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.14 | Cagr: 220.0%
 [DCF] Fair Price = unknown (Cash Flow -50.3m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.17 | # QB: 0
Revenue Correlation: 31.17 | Revenue CAGR: 11.36% | SUE: -4.0 | # QB: -1
EPS current Year (2026-06-30): EPS=-0.49 | Chg30d=+5.77% | Revisions=-20% | GrowthEPS=+34.6% | GrowthRev=+572.1%
EPS next Year (2027-06-30): EPS=-0.07 | Chg30d=+65.00% | Revisions=+20% | GrowthEPS=+85.7% | GrowthRev=+73.3%
[Analyst] Revisions Ratio: -20%